Castle Biosciences, Inc. (CSTL)
| Previous close | 16.94 |
| Open | 16.72 |
| Bid | 16.68 x 1800 |
| Ask | 16.73 x 800 |
| Day's range | 16.37 - 16.79 |
| 52-week range | 9.26 - 30.08 |
| Volume | |
| Avg. volume | 592,258 |
| Market cap | 447.588M |
| Beta (5Y monthly) | 0.80 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Motley Fool
Why Castle Biosciences Stock Is Jumping Today
The nice gain came after the genetic testing company announced its second-quarter results following the market close on Wednesday. Castle reported Q2 revenue of $50 million, a year-over-year (YOY) increase of 44%. The company posted a net loss in the second quarter of $18.8 million, or $0.70 per share.
- Zacks
Here's What Key Metrics Tell Us About Castle Biosciences, Inc. (CSTL) Q2 Earnings
While the top- and bottom-line numbers for Castle Biosciences, Inc. (CSTL) give a sense of how the business performed in the quarter ended June 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
- Zacks
Castle Biosciences, Inc. (CSTL) Reports Q2 Loss, Tops Revenue Estimates
Castle Biosciences, Inc. (CSTL) delivered earnings and revenue surprises of 30.69% and 15.25%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
